Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report-Reference-Cited by-同舟云学术

Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report

Published:2023-03-30 Issue:5 Volume:25 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Wang Xiaofang¹,Mi Xiao²,Li Teng³,Li Chengcheng²

Affiliation:

1. Health Management Center, First Affiliated Hospital of Army Medical University (Third Military Medical University), Chongqing 400038, P.R. China

2. Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China

3. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Reference20 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

3. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: A systematic review and meta-analysis;Zhou;J Immunother Cancer,2018

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial;Herbst;Lancet,2016

5. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;Clinical Lung Cancer;2024-06

2. Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;2024-01-05

3. IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers;Clinical and Translational Medicine;2023-08-30

4. Cisplatin/gemcitabine/nivolumab;Reactions Weekly;2023-06-10